|
|
 |
| |
|
Home > Drug Companies > Mission Pharmacal Company
Mission Pharmacal Company
Mission's growth as a pharmaceutical company has been fueled by its commitment to research and providing the highest quality products. The firm is dedicated to ensuring that its products are available in the best therapeutic forms. Ever expanding, state of the art technologies are the tools for their dedicated and highly-skilled employees. The firm is prepared to continue its growth today, tomorrow, and in to the next century.
Mr. Walsdorf, a pharmacist and visionary, set the stage for pharmaceutical breakthroughs with the philosophy that most existing pharmaceutical formulations had the potential to be more therapeutically effective. He often said that, a pharmaceutical product is no better than the purity and quality of the raw materials that go in to its production.
Citracal Ultra Dense calcium citrate, their flagship brand, has been cited in numerous clinical studies for its optimal solubility, and its proven ability to help stop bone loss. Citracal has earned the recognition and respect of the medical community.
Mission Pharmacal over the counter products illustrate the impact of solid medical research applied to non prescription therapeutics. Citracal is a prime example. Other products under the Mission Pharmacal banner of excellence include Calcet, for the prevention of leg cramps after exercise, Fosfree, a phosphorous-free iron, calcium, and multivitamin supplement, and Thera Gesic, a greaseless creme for relief of muscle aches and pains.
The firm has directed much of its resources to the research and development of therapeutics and diagnostic procedures for the treatment and prevention of kidney stone disease. A strong commitment to this Orphan Disease has led to the development and marketing of three Orphan Drugs that are Lithostat for the treatment of chronic urea splitting urinary infections, Thiola for the prevention of cystine stone formation, and Urocit for the treatment of recurrent nephrolithiasis and uric acid lithiasis. These innovative drugs are considered major advances in the medical management of kidney stone disease.
Continuity of the Walsdorf family contributes to the strength of Mission. After more than 50 years of excellence, this vibrant, Texas-based company is still privately held. The founding family is in its third generation. Neill B. Walsdorf, Jr., President, carries on the traditions of quality and value established by his grandfather and carried on by his father.
Back to Drug Companies
|
|
|
|
|
|
|
|